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Abstract 
Cancer is one of the leading causes of death worldwide. Biological hallmarks such as induced and 
sustained angiogenesis are implicated in tumour progression, as well as invasion and metastasis which 
are the major causes of cancer-related mortality. E-Cadherin impairment on the cell membrane is 
intimately related with invasion and metastasis. Also, increased levels of vascular endothelial growth 
factor (VEGF), an angiogenic marker, and its receptor on the plasma membrane can be implicated in 
tumour progression.   
This work was focused on how the inactivation of E-Cadherin, a molecule associated to an invasive 
phenotype can be related with angiogenesis, probably through VEGF-A expression.  
Two different cell lines without expression of E-Cadherin and stably transduced to express wild-type 
(WT) E-Cadherin were used to carry out this study: AGS Par/WT (from stomach) and MDA-435 
Mock/WT (from breast). Immunohistochemical staining was performed to determine the cellular 
localization and western blot analysis was performed to assess the expression levels of E-Cadherin. 
VEGFA mRNA levels were assessed by quantitative Real-time PCR. Additionally, we determined the 
levels phosphorylated (phospho) ERK1/2, as well as the expression levels of total ERK1/2. To study 
the angiogenic role of E-cadherin the chick embryo Chorioallantoic Membrane (CAM) assay was 
used. We characterise in vivo the different cell lines concerning both angiogenic and tumorigenic 
responses dependent on E-Cadherin.  
Only cell lines stably expressing WT human E-Cadherin showed levels of expression of this protein at 
the cell membrane regardless of their tissue of origin. In vitro, AGS and MDA-435 cells expressing 
WT E-Cadherin revealed an increased expression of VEGFA in comparison to the control although not 
statically significant.  In addition, both phospho-ERK1/2 and total ERK1/2 presented similar levels of 
expression regardless of the tissue of origin and E-Cadherin expression. Both angiogenic and 
tumorigenic responses in AGS WT was significantly increased in comparison to the control. The 
MDA-435 WT cells revealed increased tumorigenic response in comparison to the control. Overall, 
these results suggest that E-Cadherin expression is important for micro-tumour formation as well as 
for neovascularisation but this effect is dependent on the in vivo context. 
 
Key words: Cancer; E-Cadherin; (Tumour-) Angiogenesis; VEGF-A  
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Resumo 
O cancro ainda é uma das principais causas de morte no mundo. Processos biológicos como a 
angiogénese e a invasão ou as metástases, associados à progressão tumoral, são a maior causa de 
morte relacionada com esta doença. A diminuição de Caderina-E na membrana celular está 
directamente relacionada com o processo de invasão celular. Do mesmo modo, o aumento dos níveis 
do factor de crescimento vascular endotelial (VEGF, em inglês), um marcador angiogénico, e do seu 
receptor na membrana plasmática podem implicar um estado avançado da doença. 
O objectivo do trabalho foi tentar compreender como é que a Caderina-E, uma molécula associada a 
um fenótipo invasivo pode estar relacionada com a angiogénese, provavelmente através da produção 
de VEGF-A. 
Duas linhas celulares diferentes sem expressão de Caderina-E e estavelmente transfectadas para 
expressar Caderina-E “wild-type” (WT) foram utilizadas para realizar este estudo: AGS Par / WT (de 
estômago) e MDA-435 Mock / WT (de mama). As técnicas de Imunohistoquímica e Western Blot 
foram utilizadas para determinar a localização celular e a expressão proteica de Caderina-E, 
respectivamente. Os níveis de mRNA do VEGFA foram determinados por Real-time PCR. Os perfis 
de expressão de ERK1/2 fosforilada e total foram avaliados por Western Blot. O estudo do papel 
angiogénico da Caderina-E foi avaliado pelo ensaio da membrana corioalantóide (CAM, em inglês) de 
embrião de galinha. Caracterizou-se in vivo as diferentes linhas celulares no que a respeito às respostas 
angiogénica e tumorigénica dependentes da Caderina-E. 
As linhas celulares que expressam Caderina-E WT apresentaram níveis de expressão da proteína na 
membrana celular, independentemente do tecido de origem. A coloração por imunohistoquímica 
revelou marcação positiva nas mesmas linhas celulares. As células AGS e MDA-435 que expressam 
Caderina-E apresentam um aumento não-significativo de expressão de VEGFA. O perfil de expressão 
das proteínas ERK1/2 apresentou níveis semelhantes nas linhas celulares, independentemente do 
tecido de origem e de expressão de Caderina-E. As células AGS WT apresentaram um aumento em 
ambas as respostas angiogénica e tumorigénica. As células MDA-435 WT mostraram um aumento na 
resposta tumorigénica em comparação ao controlo. Em conclusão, estes resultados sugerem que a 
Caderina-E é importante na formação de micro-tumores e na neovascularização, mas o seu efeito está 
dependente do contexto in vivo. 
 
Palavras-chave: Cancro; Caderina-E; Angiogénese (tumoral); VEGF-A  
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1. Introduction 
1.1. Cancer 
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide 
accounting for about 7.6 million deaths in 2008, which correspond to 13% of all deaths. Remarkable 
differences can be found in the incidence and death rates of specific forms of cancer around the world 
(Figures 1a and 1b; IARC, GLOBOCAN 2008). For example, lung, stomach and liver cancer are the 
top three leading types of cancer associated mortality (18.2%, 9.7% and 9.2%, respectively) (Figure 
1a; IARC, GLOBOCAN 2008). The same is not observed when analysing cancer incidence: lung 
(12.7%), breast (10.9%) and colorectal cancer (9.8%) (Figure 1b; IARC, GLOBOCAN 2008).  
 
Figure 1 – Worldwide types of cancer mortality (a) and incidence (b) and world distribution of cancer mortality (c) 
and incidence (d) (age-standardised rates/100,000population) in year 2008 for both sexes and all ages (IARC, 
GLOBOCAN 2008).   
In addition, other factors can be associated with cancer risk differences, such as environment and 
culture (Figures 1c and 1d; IARC, GLOBOCAN 2008). Geographical variation studies of migrant 
populations have shown that subsequent generations of migrant individuals appear to acquire 
gradually the risk levels of the host country.  
Although, insights into the possible causes of cancer can be obtained by epidemiologic studies that 
relate environment and racial and cultural influences to the occurrence of malignant neoplasms, cancer 
is a disorder of cell invasion and in the majority of cases also of cell growth and ultimately, the causes 
should be defined at the tissue, cellular and subcellular levels (Hanahan and Weinberg 2000). 
Cancer, the common designation for malignant tumour is characterized by the uncontrolled ability of 
cells to cross and invade physical barriers. These cells are able to invade the surrounding tissue and 
frequently metastasize to distant organs, which is the major cause of death from cancer (van Zijl, 
Master Thesis - Introduction 
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Krupitza et al. 2011) All types of cancer share similar characteristics. Normal mammalian cells have 
molecular mechanisms regulating their growth, differentiation, and death. Once a group of cells escape 
these normal regulatory mechanisms, progressively acquire the ability to infiltrate and invade locally. 
Hereby, cells have the opportunity to spread and generate metastasis, marking unequivocally a tumour 
as malignant (Hanahan and Weinberg 2000).  
Cancer initiation is a multi-step process where cells accumulate a series of genetic alterations (Bertram 
2000; Hanahan and Weinberg 2000). Nonlethal genetic alterations or mutations are the main cause for 
cancer initiation, leading to a process of transformation. Such mutations may be acquired by the action 
of environmental agents or be inherited in the germline (Cornelisse and Devilee 1997). Genetic 
instability of cancer cells seems to be the more accurate system to explain cancer progression. 
Genomic instability is broadly classified into microsatellite instability (MSI) and chromosome 
instability (CIN) (Charames and Bapat 2003). For this matter, microsatellite instability (MSI) involves 
small mutations in microsatellites regions (short sequences of a few base pairs in length that are 
repeated multiple times). The insufficiency of DNA mismatch repair system during DNA replication is 
the main cause for the increased rate of mutations at the nucleotide level. Also, chromosomal 
instability (CIN) may be responsible for the insufficiency in chromosome segregation checkpoints, 
due to the chromosomal gains or losses (Jallepalli and Lengauer 2001). 
There are two main classes of regulatory genes that appear to be targets for genetic alterations, tumour 
suppressor genes and oncogenes (Cornelisse and Devilee 1997; Bertram 2000). Changes in both these 
genes can trigger cancer, either by the silencing of tumour protective genes or the activation of tumour 
promoting genes, respectively.   
Oncogenes derive from proto-oncogenes. Structural alterations or changes in the regulation of gene 
expression, can transform proto-oncogenes into oncogenes. The main difference between them is that 
proto-oncogenes promote normal growth and differentiation, whereas oncogenes once activated 
synthesize abnormal gene product or enhance the production of the normal protein (Cornelisse and 
Devilee 1997; Rak and Yu 2004). 
On the contrary, tumour suppressor genes are crucial for inhibition of cell division, as well as survival 
or other properties of tumour cells. Therefore, both alleles must be damaged for transformation to 
occur. The main causes for tumour suppressor genes inactivation are point mutations, deletions or 
insertions in sites that are essential for expression or function, as well as epigenetic silencing by 
promoter methylation or overexpression of transcription repressors (Yeo 1999; Sherr 2004). 
Alterations in these two sets of genes may lead, for example, to increased cell division and aberrant 
differentiation. Hanahan and Weinberg have recently reviewed that the organizing principles of 
malignant tumours have undergone a conceptual progress in the last decade (Hanahan and Weinberg 
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2000; Hanahan and Weinberg 2011). The classical hallmarks of cancer are: 1) resistance to cell death; 
2) self-sufficiency in growth signals; 3) insensitivity to growth inhibitory signals; 4) limitless 
replicative potential; 5) sustained angiogenesis; 6) tissue invasion and metastasis. More recently, 
deregulation of cellular energetics, evasion from immune destruction, genome instability and mutation 
as well as tumour-promoting inflammation, have been added as novel cancer hallmarks. Although, all 
the hallmarks are responsible for the events occurring in carcinogenesis and dictate tumour growth, 
which depend on the imbalance between cell production and cell loss, induced and sustained 
angiogenesis is a biological hallmark for malignant progression. Here, blood supply is crucial to 
tumour maintenance and growth, which cannot enlarge beyond 1 to 2 mm in diameter unless it is 
vascularised. Also, invasion and metastasis are biological hallmarks of malignant tumours and the 
major cause of cancer-related mortality. 
 
1.2. E-Cadherin 
The human E-Cadherin is encoded by the CDH1 gene located in the long arm of chromosome 16, 
16q22.1 (Figure 2). The gene comprises 16 exons and 15 introns and the coding region is translated 
into a 120kDa protein (www.ensembl.org). The intron-exon boundaries are highly conserved and the 
5’ CpG island is highly-dense, where introns 1 and 2 appear to have a regulatory role in addition to the 
promoter region and the latter is unusually large (Berx, Staes et al. 1995). 
 
Figure 2 – Location within the long arm of the chromosome 16, 16q22.1 (a) of the CDH1 gene (b) (adapted from (van 
Roy and Berx 2008). 
E-Cadherin is a member of the superfamily of Cadherins, a family of adhesion molecules 
characterized by a Ca2+-dependent cell-cell adhesion (Hulpiau and van Roy 2009). The Cadherins 
family are organized comprising three main domains: a short cytoplasmic domain, a single 
transmembrane segment, and a large extracellular domain with five Cadherin motifs or EC domains. 
These domains are characterized by being tandemly repeated domains responsible for their cell-cell 
adhesive function (van Roy and Berx 2008). The first to be identified and most studied was the 
“classical” Cadherins is E-Cadherin, due to its wide expression in all epithelial tissues (Hulpiau and 
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van Roy 2009). Also, its role in the different regulatory processes have been a reason for further 
studies  (Takeichi 1995; Cavallaro and Christofori 2004). 
 
Figure 3 - Human E-Cadherin structure and binding profile scheme showing the interaction with p120 catenin (p120), 
β-catenin (β) and α-catenin (α) complex bound to actin filaments (based on Yilmaz and Christofori 2010). 
The EC domains have Ca2+-binding sites necessary for E-Cadherin stabilization in a way that cell-cell 
adhesion mediated by E-Cadherin only occurs in a Ca2+-dependent fashion. The cytoplasmic domain 
of E-Cadherin is associated with catenins that bridge the linkage with actin filaments within the 
cytoskeleton (Takeichi 1995). This association with catenins is essential to provide proper cell-cell 
adhesion. Both functional extracellular and cytoplasmic domains work together to modulate stable 
cell-cell contacts (Berx, Staes et al. 1995). The recognition and binding between neighbouring cells is 
done in a homophilic fashion by the EC1 and EC2 fragments of E-Cadherin maintained by Ca2+. 
Moreover, the cytoplasmic domain is responsible to form the complex with the cytoskeleton by 
association between catenins and actin filaments (Figure 3) (Yap, Brieher et al. 1997). 
E-Cadherin is one of the proteins specialized in the adhesive function of cells and works together 
dynamically with a variety of transmembrane glycoproteins by influencing their signalling properties 
(Ozawa and Kemler 1990; Takeichi 1995). 
E-Cadherin has also a pivotal role during embryonic development being expressed in early stages, at 
two-cell stage, allowing cell migration and morphogenesis. E-Cadherin is also involved in the 
maintenance and in the homeostasis of adult epithelial tissue integrity and structure providing the 
landmarks for cells confining them spatially (Larue, Ohsugi et al. 1994).   
A dynamic process such as Cadherin-mediated adhesion is regulated by several signal transduction 
pathways. There is also evidence that Cadherins are not only targets for signalling pathways that 
regulate adhesion, but may themselves send signals that regulate basic cellular processes, such as 
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migration, proliferation apoptosis and cell differentiation (Guilford 1999; Cavallaro and Christofori 
2001; van Roy and Berx 2008). 
1.2.1. CDH1/E-Cadherin: a Tumour/Invasion Suppressor Gene 
One of the pivotal mechanisms responsible for tumour initiation and progression is the control of 
cellular adhesion and motility (Guilford 1999). Here, E-Cadherin plays a major role in malignant cell 
transformation and especially in tumour development and progression (Takeichi 1993; Guilford 1999). 
E-Cadherin exhibits an important role during the epithelial-mesenchymal transition (EMT), which is a 
process of cell conversion that occurs during development. This process is thought to be occurring in 
an uncontrolled fashion in malignant tumours of epithelial origin (Thiery 2002). Malignant carcinoma 
cells are characterized in general by poor intercellular adhesion, loss of the differentiated epithelial 
morphology and increased cellular motility. These functional features are frequently associated with 
downregulation or a complete abrogation of E-Cadherin expression, mutation(s) of the E-Cadherin 
gene, or other mechanisms interfering with the integrity of adherent junctions (Riethmacher, 
Brinkmann et al. 1995). In human tumours, the loss of E-Cadherin-mediated cell adhesion is one rate-
limiting step correlated with the loss of epithelial morphology and with the acquisition of metastatic 
potential by the carcinoma cells. Thus, a direct role in the suppression of tumour invasion has been 
assigned to E-Cadherin (Knudson, Strong et al. 1973; Berx, Cleton-Jansen et al. 1995; Guilford 1999). 
The reduction of E-Cadherin expression is considered one of the most important events involved in 
dysfunction of cell-cell adhesion system (Vleminckx, Vakaet et al. 1991).  
Multiple mechanisms are found underlying the inactivation of E-Cadherin-mediated cell adhesion 
during tumorigenesis (Guilford 1999; Cavallaro, Schaffhauser et al. 2002). The cyclical regulation of 
E-Cadherin expression by transcriptional and post-translational mechanisms provides a complex array 
of mechanisms leading to E-Cadherin downregulation (Figure 4) . These reflect the cell’s need to 
balance proliferation with adhesion and motility (Guilford 1999). On the other hand, an irreversible 
mutation on the CDH1 gene provides a simple mechanism for E-Cadherin-mediated cell adhesion 
inactivation (Figure 4; Berx, Cleton-Jansen et al. 1995; Guilford 1999; Cavallaro, Schaffhauser et al. 
2002). 
CDH1 gene is located in a region frequently showing loss of heterozygosity (LOH) within the 16q 
chromosome, in many types of human carcinomas (Figure 4; Berx, Staes et al. 1995). Also, several 
inactivating mutations in the coding region are often observed in sporadic lobular breast cancer and 
diffuse gastric cancer. Frameshift and nonsense are frequently associated with breast cancer, rather 
than the missense mutations and in-frame deletions predominant in gastric cancers (Berx, Cleton-
Jansen et al. 1995; Guilford 1999; Oliveira, Seruca et al. 2006). Germline mutations can also occur 
and are described as the cause of Hereditary Diffuse Gastric Cancer (HDGC) syndrome (Caldas, 
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Carneiro et al. 1999; Oliveira, Seruca et al. 2006). Beyond that, E-cadherin expression can also be 
regulated at the promoter level by methylation, as well as by the direct binding of specific 
transcriptional factors (Machado, Oliveira et al. 2001). 
 
1.3. Angiogenesis 
Blood vessels are crucial to carry nutrients, oxygen and hormones to distant organs. The physiologic 
process involving the development of new blood vessels from pre-existing vascular structures is 
designated Angiogenesis (Carmeliet and Jain 2011).  
Vascular endothelial cells are the main elements of blood vessels. These cells have autocrine actions 
mediated through several molecules, being the most relevant the vascular endothelial growth factor 
(VEGF). These cells are interconnected by junctional molecules, such as vascular endothelial (VE)-
Cadherin, and are ensheathed by pericytes (Liekens, De Clercq et al. 2001; Carmeliet and Jain 2011). 
The VEGF family has few members that include VEGF-A, -B, -C, -D, -E and placenta growth factor 
(PlGF) (Ferrara 2009). VEGF-A is the main component of the VEGF family and it regulates 
angiogenesis mainly through activation of VEGF receptor-2 (VEGFR-2) present in endothelial cells. 
VEGF-A effects include vessel enlargement, increased vessel branching and maintenance of vascular 
homeostasis(Folkman and Shing 1992).  When VEGF-A is lost, failure of vascular development 
occurs (Folkman, Watson et al. 1989; McMahon 2000; Carmeliet and Jain 2011). 
The molecular basis of vessel branching (Figure 4) involves the stimulation with angiogenic factors, 
which allows the quiescent vessel to dilate and an endothelial cell is selected, the tip-cell. The 
degradation of the basement membrane is a requirement for tip-cell formation, as well as pericyte 
detachment and loosening of endothelial cell junctions. The increased permeability permits the 
extravasation of plasma proteins to deposit a provisional matrix layer, and proteases remodel pre-
existing interstitial matrix, all enabling cell migration. In response to external guidance signals tip-
cells migrate and stalk cells behind the tip-cell proliferate, elongate, form a lumen and sprout to 
establish a perfused neovessel. After fusion of neighbouring branches, lumen formation allows 
perfusion of the neovessel, which resumes quiescence by the re-establishment of junctions, deposition 
of basement membrane, maturation of pericytes and production of vascular maintenance signals 
(McMahon 2000; Carmeliet 2003; Hofer and Schweighofer 2007).  
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Figure 4 - The molecular basis of vessel branching (adapted from (Carmeliet and Jain 2011). 
New and pre-existing blood vessels are essential for tissue growth and regeneration due to the ability 
of adult endothelial cells to rapidly grow and sprout in response to physiological stimuli. However, 
blood vessels also play an important role in disease, particularly in inflammation and in tumour 
progression. 
1.3.1. Tumour Angiogenesis 
Tumour cells have a constant need for oxygen and nutrient supply which they achieve through new 
blood vessels, allowing their growth (Ross 1989). Thus, tumour vascularisation is a pivotal process for 
malignancy progression (Carmeliet and Jain 2000; Hanahan and Weinberg 2000; McMahon 2000; 
Carmeliet 2003; Hanahan and Weinberg 2011). 
The angiogenic switch and the vascular phase are the two main phases of the angiogenic cascade 
leading to tumour vascularisation (Bergers and Benjamin 2003). The angiogenic switch is 
characterised by the transition from a dormant non-vascular tumour cells mass to a highly vascularised 
and progressively outgrowing tumour (Hanahan and Folkman 1996). It is a time-restricted event 
during tumour progression where the balance between pro- and anti-angiogenic factors deflects 
towards a pro-angiogenic outcome (Folkman, Watson et al. 1989; Baeriswyl and Christofori 2009). 
During tumour progression, the angiogenic switch depends on both stimulatory and inhibitory 
molecules produced by tumour cells and on cell-surface receptors displayed by the vascular 
endothelial cells (Carmeliet and Jain 2000; Carmeliet and Jain 2011). Moreover, the newly tumour 
neovasculature is characterized by precocious capillary sprouting, excessive vessel branching, 
enlarged vessels and leakiness (McMahon 2000; Cavallaro, Liebner et al. 2006).  
Pericytes play an important role in normal tissue vasculature as mentioned, but pericytes coverage is 
also crucial to maintain a functional neovasculature within a tumour avoiding necrosis and tumour cell 
apoptosis (Folkman, Watson et al. 1989; Folkman and Shing 1992). Endothelial cells closely opposed 
to outer surfaces need pericytes coverage for mechanical and physiological support (Raza, Franklin et 
al. 2010). Moreover, tumour-associated vasculature have pericytes associated with the endothelial 
cells, even though in a loosely fashion (Folkman, Watson et al. 1989; Baeriswyl and Christofori 2009; 
Raza, Franklin et al. 2010). 
1.3.2. Assays to evaluate Angiogenesis 
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Endothelial cell migration, proliferation, differentiation and structural rearrangement are essential to 
the angiogenic process. However, other cell types are involved in tumour angiogenesis including 
tumour cells themselves and circulating blood cells (Auerbach, Auerbach et al. 1991; Staton, 
Stribbling et al. 2004). Currently, it is not possible to model or simulate this complex process in vitro.  
In vitro models to assess angiogenesis are focused predominantly on migration, proliferation and 
tubule formation by endothelial cells upon stimulatory or inhibitory response. Therefore, the 
comparison between different in vitro  systems is difficult (Auerbach, Akhtar et al. 2000). In vivo 
assays are essential to evaluate angiogenesis in conditions that reproduce more accurately tumour 
induced angiogenesis in humans. In vivo assays do not show limitations regarding the origin of 
endothelial cells or the composition of the media used for culture (Staton, Stribbling et al. 2004). 
However, limitations also exist depending on the specificity of the microenvironment and the species 
used (Auerbach, Akhtar et al. 2000; Auerbach, Lewis et al. 2003). 
1.3.2.1. Chick Embryos and the Chorioallantoic Membrane (CAM) 
assay  
In vivo angiogenic assays should be reliable, technically straightforward, easily quantifiable and, most 
importantly, physiologically relevant. Nevertheless, in vivo angiogenesis assays may also be sensitive 
to environmental alterations (Ribatti, Vacca et al. 1996; Staton, Stribbling et al. 2004). The chick 
CAM is one of the most widely used in vivo assay for studying angiogenesis and its regulators (Hasan, 
Shnyder et al. 2004; Goodwin 2007). 
The CAM is an extraembryonic membrane constituted by an ectodermal chorionic epithelium, an 
intermediate mesoderm and an endodermal allantoic epithelium (Figure 5) (Gabrielli and Accili 2010). 
The CAM development starts on day 4 of incubation by fusion of the chorion and the allantois. 
Immature blood vessels scattered in the mesoderm grow exponentially until day 8/9 and give rise to a 
capillary plexus, which mediates gas exchange with the outer environment. The capillary proliferation 
continues and from day 14 forward, the endothelial cell mitotic index declines rapidly, and the 
vascular system reaches its final arrangement on day 18 (Ribatti, Vacca et al. 1996; Gabrielli and 
Accili 2010).  
 
Figure 5 – Schematic representation of the three tissue layers of the chick CAM: the outer shell membrane (sm) where 
the chorionic epithelium (ce) is attached; the intermediate mesenchymal area (m); and the allantoic epithelium (ae) ( 
adapted from (Gabrielli and Accili 2010)).  
Cells and/or molecules can be inoculated into the CAM directly or with a variety of carriers and 
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physical supports. The test material can be introduced in small pieces of polymerized materials, such 
as biologically inert synthetic polymers or within small rings limiting the inoculation site. The 
formation of new blood vessels can afterwards be analysed in terms of number, diameter, density, 
permeability, branch point number and blood flow (Ribatti, Vacca et al. 1996; Hasan, Shnyder et al. 
2004; Gabrielli and Accili 2010).  
One disadvantage of CAM assay is that the CAM already contains a well-developed vascular network 
and the vessel permeability can affect the assessment of the effects from the test substance. Another 
limitation is that the assay is performed in an embryo and as a model may be difficult to mimic adult 
tissues responses and processes during tumour progression. Also the fact that the chick embryo is not a 
mammal can represent a disadvantage (Auerbach, Lewis et al. 2003; Hasan, Shnyder et al. 2004). 
 
1.4. E-Cadherin association with Angiogenesis 
As described in the literature, E-Cadherin and VEGF are important molecules involved in tumour 
metastasis (Gupta and Massague 2006; Oppenheimer 2006; Yilmaz and Christofori 2010; van Zijl, 
Krupitza et al. 2011). Studies revealed a clinic-pathological evidence that reduced expression of E-
Cadherin was correlated with poor tumour differentiation and deeper tumour invasion, along with an 
increased expression of VEGF-A (Bazas, Lukyanova et al. 2008; Zhou, Li et al. 2010).  Abnormal 
expressions of E-Cadherin and VEGF are frequent features in cancer tissues and may represent one of 
the early molecular changes in the development of epithelial cancer (Takeichi 1993; Bertram 2000; 
Gupta and Massague 2006; Kroemer and Pouyssegur 2008; Ferrara 2009). However, there is no direct 
relationship on the prognostic value of expression level of the components of cell-to-cell adhesion 
system and the markers of angiogenesis in cancer. 
The relation between expression of cell-to-cell adhesion molecules, i.e. E-Cadherin, and VEGF and 
clinic-pathological characteristics of tumours and survival time revealed exists (Bazas, Lukyanova et 
al. 2008; Zhou, Li et al. 2010). However, it is not clear that these molecules interact with each other. 
The presence of E-Cadherin in tumours correlates with the absence of metastases. While the level of 
VEGF expression correlates with the degree of injury (Bazas, Lukyanova et al. 2008). Along with this, 
the presence of E-Cadherin is associated with favourable prognosis is most types of cancer (Inoue, 
Kamada et al. 2002; Reddy, Liu et al. 2005). On the contrary, VEGF is a marker of unfavourable 
disease course and its expression is characteristic for late stages of the disease and shorter survival 
(McMahon 2000; Bazas, Lukyanova et al. 2008; Kroemer and Pouyssegur 2008). 
Signalling pathways have been assigned to interact with both E-Cadherin and VEGF-A (Pece and 
Gutkind 2000; Kumar, Shen et al. 2009).  
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E-cadherin may regulate the activity of MAPK, a key signalling pathway involved in cell fate 
decisions, upon the formation of cell-cell contacts among neighbouring cells (Reddy, Liu et al. 2005). 
However, it is known that MAPK signalling pathway also interplay with adherent junction molecules, 
as E-Cadherin, by inducing the expression of its transcriptional repressors (Figure 6) (Pece and 
Gutkind 2000). Together, these findings suggest a crucial role of E-Cadherin in transducing signals 
outside-in through the engagement of tyrosine kinase receptors and provide an attractive mechanism 
whereby these cell-adhesion molecules can affect cell fate decision upon cell-cell contact formation 
(Figure6; Huber et al. 2005; Qian, Karpova et al. 2004).  
  
 
Figure 6 – Scheme suggesting the interplay between MAPK signalling and E-Cadherin regulation (adapted from 
(Huber et al. 2005)).  
Furthermore, MAPK signalling pathway is also associated with VEGF-A signalling pathway, leading 
to cell proliferation, and apparently both have a stimulatory role within one another (Sekulic, Haluska 
et al. 2008; Kumar, Shen et al. 2009).   
All tissues and cell types virtually express VEGF mRNA and is particularly elevated in highly 
vascularised tissue and in tumour-derived cell lines (Berra, Pages et al. 2000; Pages, Milanini et al. 
2000). Studies have suggested a role for ERK1/2 in VEGF-induced hyperpermeability (Pages, 
Milanini et al. 2000; Breslin, Pappas et al. 2003). Growth factors are thought to activate ERK-1/2 not 
only through the Ras-Raf-MEK pathway but also through p38 and PI3K (Figure 7) (Varma, Breslin et 
al. 2002; Kumar, Shen et al. 2009; Walczak, Gaignier et al. 2011; Guo et al. 2010). Also, during cell 
culture, deprivation of oxygen mimics the necrotic hypoxic regions in solid tumours induces VEGF 
mRNA expression by both an increase in the rate of transcription but also by stabilization of its 
mRNA (Berra, Milanini et al. 2000; Berra, Pages et al. 2000; Pages, Milanini et al. 2000). MAP kinase 
signalling, a module for transducing cell surface signals to the nucleus controls cell-cycle entries, at 
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the level of vascular endothelial cells (Figure 7) (Berra, Milanini et al. 2000; Berra, Pages et al. 2000; 
Pages, Milanini et al. 2000; Ferrara 2009; Guo et al. 2010). 
 
Figure 7 – Scheme suggesting the interplay between MAPK and VEGF-A signalling pathways and co-regulation 
through VEGF-A signalling pathway and/or through MAP kinase (adapted from (Guo et al. 2010)).  
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2. Project Aims 
Cancer is still one of the leading causes of death worldwide. Biological hallmarks such as induced and 
sustained angiogenesis are implicated in tumour progression, as well as invasion and metastasis which 
are the major causes of cancer-related mortality. E-Cadherin impairment on the cell membrane is 
associated to tumour progression. Also, increased levels of VEGF, an angiogenic marker, and its 
receptor on the plasma membrane can be implicated during tumour development.  
There is an association between expression of cell-to-cell adhesion molecules, i.e. E-Cadherin, and 
VEGF and clinic-pathological characteristics of epithelial tumours and survival time (Bazas, 
Lukyanova et al. 2008; Zhou, Li et al. 2010). However, it is not clear that these molecules interact 
with each other.  
To determine whether E-Cadherin expression can be related with tumour angiogenesis it was proposed 
to: 
1. Characterize different epithelial cell lines, regarding CDH1/E-Cadherin, through: 
a. mRNA transcription 
b. protein expression 
2. Determine E-Cadherin role in tumour angiogenesis in vivo by assessing both: 
a. Angiogenic response  
b. Tumorigenic response 
3. Validate in vivo results through: 
a. VEGF-A mRNA transcription 
b. (phospho-)ERK1/2 expression  
c. E-Cadherin cellular localization in CAM tumours 
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3. Materials and Methods 
3.1. Cell Lines and Culture Conditions 
In this study two different epithelial cell lines were used: MDA-435 and AGS.  
All used cell lines endogenously lack E-Cadherin expression at protein level. In our group, stably 
expressing wild-type E-Cadherin cell lines have been previously established (MDA-435 WT and AGS 
WT). Here, parental cell line (AGS Par) or cells transfected with the empty vector (MDA-435 Mock) 
were used as control in parallel with the respective WT E-Cadherin expressing cell lines. 
AGS (Par) cells from human gastric cancer were grown in Roswell Park Memorial Institute (RPMI-
1640) medium (Gibco, Invitrogen) supplemented with 10% foetal bovine serum (FBS; HyClone, 
Thermo Scientific) and 1% Penicillin-Streptomycin (PS; Gibco, Invitrogen). The AGS WT cells 
medium was supplemented with 5 μg/mL of Blasticidin (Gibco, Invitrogen). 
The human cell line MDA-MB-435S (MDA-435), from breast cancer, was maintained in Dulbecco's 
Modified Eagle Medium (DMEM) medium (Gibco, Invitrogen) supplemented with 10% FBS and 1% 
PS. The medium for MDA-435 WT cells was additionally supplemented with 500 μg/mL of Geneticin 
(G418; Gibco, Invitrogen), and for MDA-435 Mock cells the medium was supplemented with 5 
μg/mL of Blasticidin. 
The cells were maintained in an incubator Heraeus at 37°C under a humidified atmosphere containing 
5% CO2. 
3.2. Protein Extraction and Quantification 
Cells were plated in a 6-well culture dish and maintained under the same culture conditions previously 
described.  
At approximately 80% of confluence, cell cultures were washed with phosphate buffered saline (PBS) 
solution and total cell lysates were obtained through lysis with 1% Triton X-100 (Sigma), 1% Nonidet 
P-40 (Sigma) in PBS supplemented with a protease inhibitor cocktail (Roche) and a phosphatase 
inhibitor cocktail (Sigma). Total protein lysates were obtained after centrifugation at 4°C for 20 
minutes and the resulting pellets were discarded. 
For total protein quantification, the modified Bradford proteins assay (Bio-Rad) was executed 
according to the protocol provided by the manufacture. To construct the standard curve, Bovine Serum 
Albumin (BSA; Sigma) was used in different concentrations ranging from 0,25mg/mL to 3mg/mL. 
Samples were analysed on a 96-well plate for an ELISA spectrophotometer (Bio-Rad) at 655nm. 
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3.3. SDS-PAGE and Western Blot 
Equal amounts of total protein (25μg) from each cell lysates were subjected to a 10% SDS-PAGE 
electrophoresis buffered in Running Buffer after samples mixture with Laemmli sampling buffer 1x at 
95°C for 5 minutes. Proteins were separated by molecular weight and according to their 
electrophoretic mobility under 120V for 1.5 hours. 
Resolved proteins were transferred to a Hybond nitrocellulose membrane (Amersham, GE Healthcare) 
in a Western Blot Sandwich in a wet transfer system buffered with Transfer Buffer 1x under 100V for 
1.5 hours. 
Separated proteins within the nitrocellulose membrane were blocked with 5% non-fat dry milk and 
PBS-Tween 0.5% for at least 1 hour at room temperature (RT). Proteins were probed using different 
primary antibodies targeted for proteins of interest at 4°C overnight (o/n), and horseradish peroxidise 
(HRP) conjugated antibodies were used as secondary specific targeted antibodies under mild shake for 
1 hour.  Antibodies used in WB are listed in Table 1 as well as respective dilution and blocking 
conditions. 
Table 1 - Antibodies used in WB experiments, with respective dilution and blocking conditions. 
Antibody Dilution and Blocking Time/Temp 
Primary Antibodies 
Mouse anti-E-Cadherin  
1:3000 in 5% non-fat dry milk o/n at 4°C 
(120kDa; BD Biosciences) 
Rabbit anti-p42/44 MAPK (ERK 1/2) 
1:1000 in 4% BSA o/n at 4°C 
(42/44 kDa; Cell Signaling) 
Rabbit anti-Phospho-p42/44 MAPK (Thr 202/Tyr 
204)  1:1000 in 4% BSA o/n at 4°C 
(42/44 kDa; Cell Signaling) 
Goat anti-α-tubulin 1:10000 in 5% non-fat dry 
milk 
o/n at 4°C 
(55kDa; Sigma) 
Secondary Antibodies 
Goat anti-Mouse HRP conjugated  
1:3000 in 5% non-fat dry milk 1h at RT 
(Amersham, GE Healthcare) 
Goat anti-Rabbit HRP conjugated  
1:3000 in 5% non-fat dry milk 1h at RT 
(Amersham, GE Healthcare) 
 
Immunodetection was performed using an enhanced chemiluminescense, ECL Plus, kit (Amersham, 
GE Healthcare). The chemiluminescent substrate and the enhancer solution were mixed 1:1 proportion 
and blots were obtained by exposing the membranes to photographic films (Amersham, GE 
Healthcare) for increasing time periods ranging from 1 second up to 10 minutes according to the band 
strength. 
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When membrane reprobing was intended, the membranes were first washed with an isotonic solution 
for 20minutes, incubated for 30 minutes at 50°C with a Stripping Solution (10% SDS, Tris-HCl 1M 
and β-mercaptoethanol) and washed with PBS1x for 20minutes. 
Immunoblots were quantified using Quantity One 1-D Analysis Software (Bio-Rad) and the 
background value was deduced to each protein band value. Final values correspond to normalized 
values to the loading control value, α-tubulin, of the same gel. 
3.4. RNA extraction and analysis of mRNA expression by RT–PCR and real-
time PCR 
Total RNA was extracted from AGS Par, AGS WT, MDA-435 Mock and MDA-435 WT cells using 
TriPure Isolation Reagent (Roche).  
Accordingly with the instruction manual, chloroform was added to the lysed cells to separate the 
solution in three phases. To the aqueous/upper phase was added isopropanol, after which the RNA 
pellet was obtained and washed with 75% ethanol. The excess ethanol from the RNA pellet was 
removed by air-drying or under vacuum and the RNA pellet was resuspended in Diethylpyrocarbonate 
(DEPC)-treated RNase-free water and dissolved at 55°C for 10minutes. In each step of this procedure 
was performed a centrifugation at 14000rpm for 10 minutes at 4°C and the supernatant discarded, 
unless when were obtained the three phases separation in which the organic and the interphase were 
discarded. 
Total RNA was quantified using the NanoDrop ND-1000 Spectrophotometer 
(NanoDropTechnologies) and DEPC-treated RNase-free water (DEPC-treated water) was used as 
negative control. 
RNA was used to synthesise single-strand cDNA with Superscript II Reverse Transcriptase 
(Invitrogen). Approximately 1μg of total RNA was used in a mixture with 100ng of Random Primers 
(Invitrogen) and DEPC-treated water to 12μL of volume. The mixture was heated at 70°C for 
10minutes followed by cooling it on ice for 2minutes. To each sample were added 4μL of 5x First-
Strand Buffer (Invitrogen), 2μL of DTT (0.1 M; Invitrogen), 1μL of RNA dNTPs (Bioron) with 
2.5mM each, 0,2μL RNAsin (2500U/μL; Promega), 0,75μL of  Superscript II Reverse Transcriptase 
(Invitrogen) and 0,75μL of DEPC-treated water. 
VEGFA and CDH1 expression was assessed using the Real Time PCR technique and TaqMan Gene 
Expression Assays (Hs00900055_m1 and Hs01023895_m1, respectively; Applied Biosystems). For 
each sample, approximately 40ng of cDNA were used to a final reaction volume of 10μL PCR mix 
containing: 5μL of TaqMan Master Mix (Applied Biosystems), 1.6μL of probe and 3.5μL of DEPC-
treated water. GAPDH (Hs99999905_m1; Applied Biosystems) was used as endogenous control. The 
thermal profile of the run method included two holding stages at 50°C for 2 minutes and at 95°C for 
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10 minutes, followed by 42 cycles of 95°C for 15 seconds and 60°C for 1 minute. The resulting data 
was analysed using the 7500 Software For 7500 and 7500 Fast Real-time PCR Products (v2.0.4; 
Applied Biosystems).  
3.5. Chicken Chorioallantoic Membrane (CAM) Assay 
This in vivo assay was performed to assess both tumorigenic and angiogenic potential of the different 
cell lines. 
Fertilized eggs were placed into an incubator (Termaks) with humidified atmosphere at 37.5°C 
(Embryonic Development Day 0; EDD0). The eggs were maintained horizontally and rotated several 
times a day to mimic natural incubation in early days of development. 
Subsequent to incubation, at EDD3, a portion of eggshell was removed after removing 2 mL of 
albumen with a sterile syringe and a 26/28G needle. Thus, the air sack was displaced and the inner 
membrane was detached from the eggshell. 
Prior to topic cell inoculation at EDD10, cells maintained under the conditions described previously 
were prepared through trypsin treatment, centrifugation at 1200rpm for 5 minutes and resuspended in 
serum free culture medium. Counted with a Neubauer chamber (DanLab), equal amounts of cells 
(1x106 cells/10μL/egg) from each cell type were inoculated onto the CAM, inside a silicon ring with 
3mm in diameter.  
At EDD14, the embryos were sacrificed by adding approximately 2 mL of 4% paraformaldehyde 
(PFA) fixative. After 1h, the silicon ring was carefully removed and the area of interest dissected and 
photographed in the stereomicroscope (OLYMPUS, SZX2-ILLT). Tissue samples were preserved in 
PFA 4% until further processing. 
Figure 8 summarises the key time points of the CAM assay.  Figure 9 illustrates the inoculation site 
(silicon ring) of an EDD14 chick embryo. 
 
 
Figure 8 - Timeline regarding CAM Assay procedure. 
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Figure 9 - Chick embryo at day 14 of embryonic development. 
 
3.6. Histology 
 
 
Figure 10 - Summary of tissue samples processing in paraffin-embedded sections. 
 
Processing: Previously fixed in PFA 4%, tissue samples were dehydrated by increasing 
concentrations of ethanol  (1h at 70%, 1h at 96%, 3h at 100%), cleared with xylene (3h) and infiltrated 
with paraffin (at 60°C for 2h). 
Embedding: Processed tissue samples were placed into moulds with liquid paraffin (60°C) and cooled 
forming hardened blocks. 
Staining: Haematoxylin and Eosin staining was performed in 3μm paraffin-embedded sections 
Deparaffinization and rehydration of all samples was performed with xylene, decreasing 
concentrations of ethanol (20 minutes at 100%, 5 minutes at 96%, 5 minutes at 70%, 5 minutes at 
50%) and water for 5 minutes. Samples were stained with Gill's Haematoxylin III (Thermo Scientific) 
solution for 5 seconds, differentiated with an ammonia water (0.6%) solution for 15 seconds and with 
ethanol 95% for 5 minutes and counterstained with Eosin (Thermo Scientific) solution for 5 minutes. 
Tissue samples were dehydrated with increasing concentrations of ethanol: 95% for 5 minutes, 100% 
for 10 minutes followed by clear-rite for 10 minutes and embedded with Entellan (CitoCell) mounting 
medium. 
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3.7. Immunohistochemistry 
Paraffin-embedded tissue sections with 3μm were deparaffinised and rehydrated through sequential 
incubations with xylene (30 minutes), decreasing concentrations of ethanol (100% for 20 minutes; 
96% for 10 minutes; 70% for 10 minutes and 50% for 10 minutes) and distilled water. 
E-Cadherin antigen retrieval was heat induced with citrate buffer solution (pH 6.0) at 98°C for 30 
minutes. 
Endogenous peroxidise was blocked with a 3% hydrogen peroxide (H2O2) in methanol solution for 10 
minutes, at RT. Unspecific antigens were blocked with Lab Vision Large Volume Ultra V Block 
(Dako) for 15 minutes, at RT.  
Primary antibodies anti-E-Cadherin (1:100, Cell Signalling; and 1:500, BD Biosciences) were diluted 
in Large Volume Ultra AB Diluent (Dako) and incubated at 4°C overnight. The Envision Detection 
system (Dako) was used as secondary antibody and incubated at RT for 1 hour. Immunodetection was 
executed through a peroxidase reaction by adding DAB (110μL/sample) for 3 minutes and 
counterstained with Gill's Haematoxylin I and dehydration with water (5minutes), increasing 
concentrations of ethanol (70% for 2 minutes; 96% for 2 minutes; 100% for 4 minutes) and xylene for 
5 minutes. Preparations were embedded with Entellan (CitoCell) mounting medium. 
3.8. Statistical Analysis 
For statistical analysis, the unpaired Student’s T-test with unequal population size and unequal 
variance was used to assess the expression phenotype of cells expressing E-Cadherin and cells 
negative for E-Cadherin regarding E-Cadherin itself, Phospho-ERK1/2 and ERK1/2 (by Western Blot) 
and CHD1 and VEGFA (by Real-time PCR).  
Differences in the number of newly formed blood vessels and in the area of formed micro-tumours 
regarding E-Cadherin expression within the different cell lines were determined using the same 
approach with Student’s T-test.  
P-values lower than 0.05 were considered statistically significant. 
The dependence between newly formed blood vessels and the area of formed micro-tumours, in vivo, 
was estimated using a linear regression with the Pearson correlation coefficient, r.  
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4. Results 
4.1. Characterization of E-Cadherin expressing cell lines 
Cell lines stably expressing wild-type (WT) human E-Cadherin or the empty vector have been 
established as mentioned in the Materials and Methods section. All the constructs have been stably 
transfected and transduced into mammalian E-Cadherin negative cell lines (AGS and MDA-435) and 
selected by antibiotic resistance according to the expression vector. 
 
4.1.1. Morphology 
Stomach cells, both AGS parental cell line (AGS Par) and cells expressing WT E-Cadherin, AGS WT 
presented an epithelial morphology with an adherent growth, (Figures 11a and 11b, respectively). 
 
Figure 11 - Bright field images of AGS Par (a) and WT (b) cells using an Inverted Microscope ECLIPSE TS100-F 
(Nikon) and a DS Camera Control Unit DS-L2 (Nikon) with 200x of magnification. 
Human breast cell lines, MDA-435 Mock and MDA-435 WT expressing the empty vector and the 
human WT E-Cadherin, respectively, presented an adherent growth with spindle shaped morphology 
(Figures 12a and 12b, respectively). 
 
Figure 12 - Bright field images of MDA-435 Mock (a) and WT (b) cells using an Inverted Microscope ECLIPSE 
TS100-F (Nikon) and a DS Camera Control Unit DS-L2 (Nikon) with 200x of magnification. 
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4.1.2. Protein Expression 
To confirm the human WT E-Cadherin expression in the cell lines transfected with the corresponding 
construct, a western blot analysis to detected E-Cadherin was performed in three or more separate 
biological replicates. Cells stably expressing WT E-Cadherin showed similar levels of the protein 
regardless their tissue of origin and cells transfected with the mock vector, E-Cadherin protein was 
never detected (Figure 13). 
 
Figure 13 - E-Cadherin expression levels by western blotting analysis of WT human E-Cadherin,  normalized for the 
respective loading control, α-tubulin: AGS Par and AGS WT (left, p=0.02); and MDA-435 Mock and MDA-435 WT 
(right; p=0.12). The values were normalized to the control cells: AGS Par and MDA-435 Mock, respectively. 
 
4.1.3. CDH1 mRNA transcripts Expression 
The levels of CDH1 mRNA transcripts were determined by Real-time PCR technique in three separate 
biological replicates, to understand whether E-Cadherin expression was due to the inserted construct 
or to endogenous expression of the CDH1 mRNA within the cells. AGS WT showed significantly 
higher levels of CDH1 mRNA in comparison to AGS Par (p=0.001; Figure 14a). CDH1 mRNA levels 
in MDA-435 cells, particularly in MDA-435 WT cells, presented a significant increase in comparison 
to MDA-435 Mock cells (p=0.00005; Figure 14b).  
 
Figure 14 - Relative CHD1 mRNA expression levels of: a) AGS Par (left) and WT (right) (p=0.001); and b) MDA-435 
Mock (left) and WT (right) (p=0.00005). The values were normalized to the endogenous control expression (GAPDH), 
and to the respective control cell line (AGS Par or MDA-435 Mock). 
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4.2. Effects of E-Cadherin on Angiogenesis – Neovascularisation and Micro-
tumour formation 
To evaluate whether E-Cadherin expression is directly involved in cancer-induced neovascularisation, 
the CAM assay was performed and both angiogenic and tumorigenic responses were evaluated. 
4.2.1. E-Cadherin potentiates an angiogenic response 
The angiogenic response was evaluated by counting the number of blood vessels with less than 20μm 
in diameter, growing in a wheel shape towards the inoculation site. The silicone ring delimited a 
constant area of counting.    
AGS cells expressing WT E-Cadherin showed a significant increase (p=0.02) in the number of newly 
formed blood vessels, in comparison to the parental cell line (AGS Par) (Figure 15).  
 
Figure 15 - Angiogenic response, in the CAM assay, of AGS Par and AGS WT  stomach cell lines: (a) ex ovo images of 
CAM depicting newly formed blood vessels in AGS Par (left) and WT (right); b) number of newly formed blood 
vessels in response to AGS Par (17.64±0.65; left) and WT (22.10±1.39; right). AGS WT show a significant increase 
(p=0.02) in the angiogenic response. 
For the MDA-435 Mock and WT cell lines the number of newly formed blood vessels were similar 
(p=0.49; Figure 16).  
 
Figure 16 - Angiogenic response, in the CAM assay, of MDA-435 Mock and MDA-435 WT  breast cell lines: (a) ex ovo 
images of CAM depicting newly formed blood vessels in MDA-435 Mock (left) and WT (right); b) number of newly 
formed blood vessels in response to MDA-435 Mock (12.64±0.79; left) and WT (13.65±1.23; right). MDA-435 WT did 
not show a significant increase (p=0.49) in the angiogenic response. 
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4.2.2. E-Cadherin increases the tumorigenic response 
The tumorigenic response was evaluated by assessing the percentage of micro-tumour formation and 
by measuring micro-tumours areas using Cell A Software (Olympus).  
AGS cells expressing WT E-Cadherin showed a statistically significant increase of micro-tumour area 
(p=0.006; Figures 17a and 17b). Moreover, 50% of the cases (15 out of 30 embryos), AGS WT cells 
formed micro-tumours. AGS Par cells formed micro tumours in 9% of the cases (4 out of 47 
embryos).  
 
Figure 17 - Tumorigenic response in AGS Par and AGS WT stomach cell lines: (a)  ex ovo images depicting the micro-
tumour formation in AGS Par (left) and WT (right); and b) micro-tumours areas of AGS Par (0.31±0.22; left) and 
WT (1.50±0.45; right) and the percentage of micro-tumour formation in AGS Par (8,5%; left) and WT (50%; right). 
AGS WT showed significant increase in tumour formation (p=0.006).  
MDA-435 WT cells formed significant larger (5.34±0.79 mm2) tumours than MDA-435 Mock cells 
(1.96±0.42 mm2; p=0.0006) (Figure 18b).  MDA-435 WT cells formed micro-tumours in 92% of the 
cases (24 out of 26 embryos) in comparison to MDA-435 Mock cells which formed micro-tumours in 
76% of the cases (19 out of 25 embryos). 
 
Figure 18 - Tumorigenic response in MDA-435 Mock and MDA-435 WT breast cell lines: (a)  ex ovo images depicting 
the micro-tumour formation in MDA-435 Mock (left) and WT (right); and b) micro-tumours areas of MDA-435 Mock 
(1.96±0.42; left) and WT (5.34±0.79; right) and the percentage of micro-tumours formation in MDA-435 Mock (76%; 
left) and WT (92,6%; right). MDA -435 WT showed significant increase in tumour formation (p=0.0006).  
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No correlation was observed between micro-tumour area and formation in any case. 
4.3. VEGFA mRNA expression is induced by the presence of E-Cadherin 
To evaluate if the expression of Vascular Endothelial Growth Factor – A (VEGF-A) accounts for the 
functional in vivo angiogenic responses of AGS and MDA-435 cell lines, a quantitative Real-time 
PCR was performed in three separate biological replicates. A two fold increase of VEGFA mRNA 
levels of AGS WT in comparison to AGS Par cells was observed, but  without statistical differences 
(p=0.07)  (Figure 19a). MDA-435 WT cells presented VEGFA mRNA similar to those of MDA-435 
Mock (p=0.37) (Figure 19b).  
   
 
Figure 19 - Relative VEGFA mRNA expression levels within the cell lines: a) AGS Par (left) and WT (right) (p=0.07); 
and b) MDA-435 Mock (left) and WT (right) (p=0.37). The values were normalized to the endogenous control, 
GAPDH, expression levels and to the respective control cell lines (AGS Par or MDA-435 Mock). 
 
4.4. Functional E-Cadherin is being expressed in vivo 
To confirm E-Cadherin expression in vivo, an immunostaining was performed in sections of CAM 
tumours with two different antibodies recognising WT human E-Cadherin (clone 24E10, Cell 
Signaling; and clone 36, BD Biosciences). The antibodies have different affinities towards E-
Cadherin. The antibody 24E10 was specific to human WT E-Cadherin (Figure 20) while the antibody 
36 reacted with both human and the E-Cadherin chick endogenous homolog L-CAM (Figure 21).  
The results showed a WT E-Cadherin expression, at the cell membrane, only in CAM tumours derived 
from AGS WT and MDA-435 WT transfected cells, four days after cell inoculation onto CAM (Figure 
20).   These results confirm human E-Cadherin expression during the angiogenic and tumorigenic 
assays.   
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Figure 20 - Immunohistochemical analysis of WT human E-Cadherin protein (200x of magnification) using a 24E10 
antibody (Cell Signaling). Positive immunostaining for E-Cadherin is observed only in CAM tumours derived from 
WT E-cadherin transfected cells (*). CAM tumours derived from Mock transfected cells did not express human E-
Cadherin. 
 
Figure 21 - Immunohistochemical analysis of WT E-Cadherin protein (200x of magnification) using a 36 antibody 
(BD Biosciences). Positive immunostaining for E-Cadherin is observed in CAM tumours and in CAM epithelial layers 
(arrows). Labelling intensity of CAM tumours derived from Mock transfected cells (#) is much weaker that that 
observed in CAM tumours derived from human WT E-cadherin transfected cells (*). 
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4.5. MAPK signalling pathway is activated regardless E-Cadherin expression  
MAPKs are ubiquitous intracellular signalling modulators frequently involved in cancer development 
and progression. To understand if MAPKs mediate the observed in vivo angiogenic and tumorigenic 
responses, the activation and expression profiles of ERK1/2 in all cell lines were assessed by western 
blot analysis using a phospho-specific antibody in a three or more separate biological replicates. 
Although no significant differences in ERK1/2 phosphorylation levels were detected in any of the cell 
lines (Figure 22), an increase of expression of ERK1/2 phosphorylation was observed in AGS WT 
(17.2%) and MDA-435 WT (33.6%), in comparison with to AGS Par and MDA-435 Mock, 
respectively. 
 
Figure 22 – Phospho-ERK1/2 expression levels by western blotting analysis of phosphorylated ERK1/2,  normalized 
for the respective loading control, α-tubulin: AGS Par  and AGS WT (left; p=0.74); and MDA-435 Mock and MDA-
435 WT (right; p=0.61). The values were normalized to the control cells: AGS Par and MDA-435 Mock, respectively. 
 
Immunoblotting for the total forms of this kinase revealed comparable amounts of ERK1/2 MAPK for 
all the cell lines. There is an increase of expression (4.7%) in AGS WT in comparison with AGS Par 
(Figure 23). MDA-435 WT cell line showed a decrease of 10.8% in comparison with to MDA-435 
Mock (Figures 23). 
 
Figure 23 – ERK1/2 expression levels by western blotting analysis of total ERK1/2,  normalized for the respective 
loading control, α-tubulin: AGS Par  and AGS WT (left; p=0.93); and MDA-435 Mock and MDA-435 WT (right; 
p=0.87. The values were normalized to the control cells: AGS Par and MDA-435 Mock, respectively.
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5. Discussion and Conclusions 
Cancer is still one of the causes of death worldwide. Despite all the efforts and research, the 
interaction between some cancer-associated pathways is not yet fully understood. 
As an adhesion molecule, E-Cadherin has a pivotal role balancing cell proliferation, adhesion and 
motility (van Roy and Berx 2008). During tumour initiation and progression, the disruption of E-
Cadherin-mediated cell adhesion is a necessary event in the development of epithelial tumours 
(Guilford 1999). In addition, tumours require a sustained angiogenesis for nutrients and oxygen supply 
(Hanahan and Folkman 1996). VEGF-A, as an angiogenic regulator, is a signalling protein that binds 
to stimulatory cell-surface receptors displayed by vascular endothelial cells, maintaining an 
“angiogenic switch” activated continuously (Hanahan and Folkman 1996; Bergers and Benjamin 
2003; Baeriswyl and Christofori 2009; Carmeliet and Jain 2011).  
An invasive phenotype is often characterised by E-Cadherin impairment on cell membrane was not yet 
described to be related with tumour angiogenesis on a molecular level (Hofer and Schweighofer 2007; 
Bazas, Lukyanova et al. 2008; Zhou, Li et al. 2010). Thus, both in vitro and in vivo models were 
needed to understand the role of E-Cadherin expression in tumour angiogenesis.  
To analyse and evaluate the relevance of E-Cadherin expression on tumour induced angiogenesis 
several cell lines were used which presented an epithelial (AGS) or spindle shaped (MDA-435) 
morphology from different origins: stomach (AGS Par) and breast (MDA-435). 
The cell lines were stably transfected with wild-type (WT) human E-Cadherin: AGS WT and MDA-
435 WT. All cells expressing WT E-Cadherin presented an organised growth during culturing, 
suggesting the need of cell-cell contact for “limiting” the uncontrolled growth during tumour 
development. Such growth was not observed for the control cell lines (AGS Par and MDA-435 Mock).  
To confirm that the phenotypical differences observed were indeed related to E-Cadherin presence, 
transfection efficiency had to be proven both at the mRNA and protein levels. Using quantitative Real-
Time PCR on total RNA extracted from different passages of AGS and MDA-435 cell lines it was 
observed that: 1) MDA-435 WT cells showed significantly higher levels of CDH1 mRNA whereas 
MDA-435 Mock completely lacked CDH1 mRNA (p=0.00005); 2) AGS WT cells showed 
significantly higher levels of CDH1 mRNA in comparison to AGS Par cells that presented residual 
CDH1 transcription (p=0.001). The expression of CDH1 transcripts in parental AGS cells has been 
previously described and the detected transcripts are known to lead to a truncated form of the protein 
(Oliveira C, unpublished). To confirm this, Western Blot analysis of total lysates of different cell 
passages was performed. In fact, AGS Par did not express WT E-Cadherin, similarly to MDA-435 
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Mock. Moreover, it was observed that all stably WT E-Cadherin transfected cell lines were expressing 
the cell-cell adhesion protein. 
To understand the effect of E-Cadherin introduction into the selected cell lines, in terms of their 
angiogenic and tumorigenic potential, the chick CAM assay was performed. Tumorigenic potential 
was first evaluated in terms of micro-tumour area, as a function of size. AGS WT cells showed a 
significant increase in both angiogenic (p=0.02) and tumorigenic (p=0.006) responses in comparison 
to AGS Par cells. MDA-435 WT cells showed a significantly increased tumorigenic response 
(p=0.0006) despite showing no differences in terms of angiogenic potential (p=0.49). The assessment 
of the angiogenic response was difficult to determine due to the morphology of the CAM tumours. 
These results highlight a role for E-cadherin: its effects on angiogenesis may depend on a specific 
genetic background of cells.  
The tumorigenic potential, via chick CAM assay, can also be analysed in light of micro-tumour 
formation. AGS WT cells showed micro-tumour formation in 50% of the embryos rather than the 9% 
of the embryos observed in the absence of E-Cadherin (AGS Par). MDA-435 WT cells also showed an 
increased percentage of micro-tumour formation (92%) in comparison to the control, MDA-435 Mock 
(76%).  However, no correlation was observed between the size of formed tumours and the percentage 
of formation. 
In conclusion, cells expressing WT E-Cadherin showed a regular outcome concerning the number of 
newly formed blood vessels and also the occurrence of micro-tumour formation and size. Cells 
expressing WT E-Cadherin presented always a higher number of newly formed blood vessels, as well 
as larger and more frequent micro-tumours in comparison with cells lacking E-Cadherin. These results 
suggest that E-Cadherin might be responsible for cell aggregation within the cells inoculated onto the 
chick CAM. Thus, it is likely that cell aggregates larger than 1mm2 in diameter show an increased 
neovasculature due to their need for nutrients and therefore the need for blood supply (Carmeliet and 
Jain 2000; McMahon 2000). 
To understand whether the angiogenic response observed in the in vivo assay was mediated by VEGF-
A and if it could be related with E-Cadherin presence, the VEGFA mRNA levels were assessed. Using 
the same approach as previously mentioned for CDH1, it was observed that AGS WT and MDA-435 
WT, showed increased levels of VEGFA mRNA (p=0.07and p=0.37, respectively). Not negligible was 
the presence, although at lower levels, of VEGFA transcription in both mock (MDA-435 Mock) and 
parental (AGS Par) cells, which also displayed micro-tumour formation (76% and 9%, respectively) 
and a certain degree of neovascularization. The detected transcription of VEGFA mRNA within 
control cells could underlie the observed angiogenic response in vivo. 
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Furthermore, the increased levels of transcription of VEGFA mRNA displayed by cells expressing WT 
E-Cadherin (MDA-435 WT and AGS WT) are in agreement with the in vivo functional results, where 
the angiogenic response was increased in the presence of E-Cadherin. In fact, all tissues and cell types 
virtually express VEGFA mRNA and is particularly elevated in highly vascularised tissue and in 
tumour-derived cell lines (Berra, Pages et al. 2000; Pages, Milanini et al. 2000). Thus, these results 
suggest that the presence of functional E-Cadherin might in fact induce an increased expression of 
VEGFA that in turn, mediates the observed increased angiogenic response. 
E-Cadherin expression/presence during the in vivo assays was determined by immunohistochemistry 
using two different antibodies recognizing human E-Cadherin. All cell lines expressing WT E-
Cadherin (AGS WT and MDA-435 WT) showed E-Cadherin at the plasma membrane in all tested 
CAM micro-tumours sections. However, the used antibodies showed different affinities towards E-
Cadherin: the clone 24E10 (Cell Signaling) was human-specific and reacted only with human E-
Cadherin; while the clone 36 (BD Biosciences) was not so specific and reacted also with the chick 
endogenous homolog, L-CAM, expressed at the CAM. Nevertheless, the clone 36 antibody presented 
an increased intensity in human E-Cadherin expressing tissue samples (AGS WT and MDA-435 WT), 
rather than in the controls (AGS Par and MDA-435 Mock). These results confirmed functional E-
Cadherin at the plasma membrane during both angiogenic and tumorigenic in vivo assays. 
It was hypothesized that the increased tumorigenesis and angiogenesis upon E-cadherin presence 
could be due to MAP kinases signalling. To understand if p42/44 MAPKs (ERK1/2) mediate the 
observed in vivo responses, the activation and expression profiles in all cell lines were assessed by 
western blot analysis. The results showed similar levels of phospho-ERK1/2 in all cell lines regardless 
of E-Cadherin expression: AGS WT and MDA-435 WT showed a non-significant increase of 
expression (17%, p=0.74 and 34%, p=0.61, respectively). Likewise, total levels of ERK1/2 were 
similar amongst all cell lines: 1) AGS WT showed a non-significant increase of expression (5%, 
p=0.93); and 2) MDA-435 WT cells showed a non-significant decreased expression (11%, p=0.87).  
It is known that VEGF-A, as a stimulatory agonist, binds to its receptor expressed on the endothelial 
surface, VEGFR-2, thus triggering multiple intracellular signalling cascades (Berra, Pages et al. 2000; 
Breslin, Pappas et al. 2003; Cuenda and Rousseau 2007; Ferrara 2009). Among others, this binding 
can activate the MAP kinase cascade characterised by the phosphorylation of ERK1/2, a downstream 
effector (Berra, Milanini et al. 2000; Pages, Milanini et al. 2000; Varma, Breslin et al. 2002; Breslin, 
Pappas et al. 2003). The observed results showed that E-Cadherin expression increased VEGF-A 
expression. However, control cells already displayed a basal level of VEGF-A. Therefore, it is 
possible to assume that such basal level is enough for MAPK pathway activation and that the 
increased VEFG-A expression due to E-Cadherin presence was not enough to observe an over-
activation of this pathway.  
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The expression of WT E-Cadherin within the cells inoculated onto the chick CAM induced the 
formation of micro-tumours. Knowing that: 1) larger tumours (>1mm2) have the need for 
neovascularisation (Carmeliet and Jain 2000; McMahon 2000); 2) VEGF-A could induce cell motility 
and proliferation through MAPK signalling pathway (Berra, Milanini et al. 2000; Berra, Pages et al. 
2000; Kumar, Shen et al. 2009; Walczak, Gaignier et al. 2011); 3) WT E-Cadherin is being 
constitutively expressed; and 4) functional E-Cadherin rescue prevents an invasive phenotype 
(Christofori and Semb 1999; Guilford 1999), it was hypothesised E-cadherin prevention of cell 
migration lead to larger micro-tumours which needed nutrients and oxygen, hence explaining the 
increased neovascularisation. However, cells lacking total expression of E-Cadherin also showed 
neovascularisation and in some cases the formation of micro-tumours. This could be explained by the 
observed basal levels of VEGFA as well as ERK1/2 levels.  
In conclusion, in this study it was demonstrated that E-Cadherin is associated with increased levels of 
VEGF-A. Moreover, we show that E-cadherin in AGS and MDA-435 lead to an increased tumorigenic 
response. Although both cell lines show distinct neovascularisation responses this response is not 
dependent on MAPK signalling pathway (ERK1/2).  In contrast, the overall results suggest that the 
angiogenic response to E-Cadherin expression is dependent on the type of cell line in a specific 
genetic background. 
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6. Future Perspectives 
E-Cadherin is an adhesion molecule expressed in normal epithelial tissues. Its expression in cancer 
cells derived from epithelia is frequently absent or present abnormal features (Guilford 1999; van Roy 
and Berx 2008). The ability of cancer cells to migrate and invade to surrounding tissues, implicate 
cytoskeleton rearrangement (Guilford 1999; van Roy and Berx 2008). External and pro-angiogenic 
growth factors control these events in a coordinated fashion. In addition, a sustained angiogenesis 
helps to maintain tumour homeostasis and supply, for example via increased VEGF-A expression. 
In this thesis was demonstrated that E-Cadherin may play a direct role in tumour angiogenesis 
induction. A possible interplay between E-Cadherin and VEGF-A has been identified with E-Cadherin 
presenting a dual role regarding tissue specificity. On one hand its presence induced higher levels of 
VEGFA, inducing increased neovascularisation in gastric cells. On the other hand, in E-Cadherin’s 
absence, neovascularisation was still observed in breast cells, although at lower levels, in what appears 
to be a tissue-dependent response. In this regard, some important questions remain unclear: 
 Are in vivo observations, regarding E-Cadherin expression, being affected by specific cell line 
programme? 
 How can in vivo observations differ in a tissue-dependent fashion, regardless of E-Cadherin 
expression? 
 What are the molecules mediating angiogenesis within the context of this study and how do 
they vary according to E-Cadherin expression? 
This could be achieved by pursuing both in vitro and in vivo studies. A classical approach would be to 
establish an in vitro system with which to manipulate E-Cadherin (by downregulation or by 
overexpression) aiming at better clarifying its interplay with angiogenesis (VEGF-A expression, MAP 
Kinase pathway activation, etc).  
To complement this approach, E-Cadherin expressing cell lines could be injected in a different in vivo 
model out of the embryonic context, as nude mice. Such model could have simple readouts such as 
tumour formation and tumour size. In the event of tumour formation in an E-Cadherin dependent 
manner, immunohistochemical studies could help to understand E-Cadherin impact on tumorigenesis. 
Another aspect is that VEGF-A expression should provide an insight regarding an angiogenic response 
related with tumours. Moreover, further investigation on MAP kinase cascades should provide 
information on in vivo cell behaviour regarding cell motility and proliferation, through p38 MAPK 
activation and the upstream effectors of ERK1/2 pathway.  
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These and other studies could complement the work presented in this Thesis thus enlightening the role 
of CDH1/E-Cadherin in cancer angiogenesis.     
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